GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Savara Inc (NAS:SVRA) » Definitions » Cyclically Adjusted PB Ratio

Savara (Savara) Cyclically Adjusted PB Ratio : 0.74 (As of May. 15, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Savara Cyclically Adjusted PB Ratio?

As of today (2024-05-15), Savara's current share price is $4.83. Savara's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $6.51. Savara's Cyclically Adjusted PB Ratio for today is 0.74.

The historical rank and industry rank for Savara's Cyclically Adjusted PB Ratio or its related term are showing as below:

SVRA' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.01   Med: 0.06   Max: 0.74
Current: 0.74

During the past years, Savara's highest Cyclically Adjusted PB Ratio was 0.74. The lowest was 0.01. And the median was 0.06.

SVRA's Cyclically Adjusted PB Ratio is ranked better than
71.23% of 643 companies
in the Biotechnology industry
Industry Median: 1.78 vs SVRA: 0.74

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Savara's adjusted book value per share data for the three months ended in Mar. 2024 was $0.882. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $6.51 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Savara Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Savara's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Savara Cyclically Adjusted PB Ratio Chart

Savara Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.10 0.04 0.06 0.12 0.62

Savara Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.18 0.33 0.44 0.62 0.77

Competitive Comparison of Savara's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Savara's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Savara's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Savara's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Savara's Cyclically Adjusted PB Ratio falls into.



Savara Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Savara's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=4.83/6.51
=0.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Savara's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Savara's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.882/129.4194*129.4194
=0.882

Current CPI (Mar. 2024) = 129.4194.

Savara Quarterly Data

Book Value per Share CPI Adj_Book
201406 29.333 100.560 37.751
201409 24.841 100.428 32.012
201412 25.750 99.070 33.638
201503 21.994 99.621 28.573
201506 18.198 100.684 23.392
201509 14.349 100.392 18.498
201512 10.220 99.792 13.254
201603 7.507 100.470 9.670
201606 5.519 101.688 7.024
201609 3.964 101.861 5.036
201612 -9.858 101.863 -12.525
201703 1.195 102.862 1.504
201706 3.296 103.349 4.127
201709 3.061 104.136 3.804
201712 3.911 104.011 4.866
201803 3.062 105.290 3.764
201806 2.682 106.317 3.265
201809 3.356 106.507 4.078
201812 3.079 105.998 3.759
201903 2.841 107.251 3.428
201906 2.899 108.070 3.472
201909 2.592 108.329 3.097
201912 2.002 108.420 2.390
202003 1.717 108.902 2.040
202006 1.586 108.767 1.887
202009 1.415 109.815 1.668
202012 1.189 109.897 1.400
202103 1.542 111.754 1.786
202106 1.453 114.631 1.640
202109 1.363 115.734 1.524
202112 1.267 117.630 1.394
202203 1.197 121.301 1.277
202206 1.114 125.017 1.153
202209 1.022 125.227 1.056
202212 0.945 125.222 0.977
202303 0.861 127.348 0.875
202306 0.768 128.729 0.772
202309 1.083 129.860 1.079
202312 1.016 129.419 1.016
202403 0.882 129.419 0.882

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Savara  (NAS:SVRA) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Savara Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Savara's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Savara (Savara) Business Description

Industry
Traded in Other Exchanges
Address
6836 Bee Cave Road, Building I, Suite 205, Austin, TX, USA, 78746
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
Executives
Matthew Pauls director 9 DEER PARK DRIVE, SUITE C, MONMOUTH JUNCTION NJ 08852
David L Lowrance officer: Chief Financial Officer 422 WILLIAM WALLACE DRIVE, FRANKLIN TN 37064
Nevan C Elam director C/O NEKTAR THERAPEUTICS, 150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Rick Yang 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Scott D Sandell 10 percent owner
Forest Baskett 10 percent owner
Florence Anthony A. Jr. 10 percent owner 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Ali Behbahani 10 percent owner 5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Mohamad Makhzoumi 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Paul Edward Walker 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Carmen Chang 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Edward T Mathers 10 percent owner C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Growth Equity Opportunities 17, Llc 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Raymond Dennis Pratt officer: Chief Medical Officer 208 E CHASE ST, BALTIMORE MD 21202
David A Ramsay director HALOZYME THERAPEUTICS, INC., 11588 SORRENTO VALLEY ROAD, #17, SAN DIEGO CA 92121

Savara (Savara) Headlines

From GuruFocus

Savara Announces New Employment Inducement Grant

By Business Wire 10-06-2023

Savara Announces New Leadership Appointments

By Business Wire Business Wire 02-14-2023

Savara to Present at the Jefferies Healthcare Conference

By Business Wire Business Wire 06-02-2023

Savara to Participate in Three Upcoming Investor Conferences

By Business Wire Business Wire 11-09-2022

Savara Announces New Employment Inducement Grant

By Business Wire Business Wire 01-20-2023

Savara Announces New Employment Inducement Grant

By Business Wire Business Wire 11-22-2022